Andrzej Kawecki

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Robert I. Haddad, Kevin J. Harrington, Makoto Tahara et al. · Journal of Clinical Oncology · 2022 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck

Andrzej Kawecki, Douglas R. Adkins, Casey Cunningham et al. · Journal of Clinical Oncology · 2007 · 26 citations

Medicine, Oncology, Pharmacotherapy +16

5501 ORAL Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME)

Jan B. Vermorken, Ricardo Hitt, Lionnel Geoffrois et al. · European Journal of Cancer Supplements · 2007 · 18 citations

Medicine, Oncology, Cancer Pharmacology +7